Added to YB: 2025-10-27
Pitch date: 2025-10-26
IDXG [bullish]
Interpace Biosciences, Inc.
+26%
current return
Author Info
No bio for this author
Company Info
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States.
Market Cap
$38.3M
Pitch Price
$5.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
7.04
P/E
1.52
EV/Sales
1.01
Sector
Health Care Providers and Services
Category
turnaround
Trading at 7x Estimated Earnings Post-Restructuring
IDXG: Post-restructuring thyroid diagnostics play at ~7x est earnings, 0.72x EV/Rev vs peers VCYT/MDxH at 2.5-4x. PancraGEN loss dropped stock -70% to $0.93. Q3 catalyst: SG&A cuts reveal ~$4-6M EBIT power on $35M rev, 16% vol growth taking share. Kamin involved. Risks: illiquid ($6k/day), CLFS reimbursement reset 2026, going dark. 100%+ upside at 1.5x EV/Rev.
Read full article (8 min)